TY - JOUR
T1 - The role of anti-α-actinin antibodies in the pathogenesis and monitoring of lupus nephritis
AU - Youinou, Pierre
AU - Putterman, Chaim
N1 - Funding Information:
The authors acknowledge the important contributions of Yves Renaudineau (Brest, France) to several of the studies cited in this editorial. Studies in the laboratory of CP are funded by the National Institute of Arthritis and Musculoskeletal Disease, the National Institute of Diabetes and Digestive and Kidney Diseases, and the Lupus Research Institute.
PY - 2009/12/11
Y1 - 2009/12/11
N2 - Antibodies to double-stranded DNA are important in the pathogenesis of nephritis, a major clinical manifestation in lupus patients. Since earlier diagnosis of renal involvement may lead to better outcomes, identification of the nephritogenic specificity of lupus-associated autoantibodies is important in understanding the disease, while monitoring their titer clinically may serve as an improved biomarker. Based upon work in animal models and crosssectional human studies, kidney a-actinin was thought to be a plausible cross-reactive target for pathogenic lupus antibodies. Manson and colleagues longitudinally evaluated anti-nucleosome, anti-DNA, and anti-a-actinin antibodies in 16 lupus patients with new-onset nephritis. While anti-nucleosome and anti-DNA antibody levels were significantly associated and correlated with measures of kidney disease, these were not found to be significant with anti- a-actinin antibodies. While in lupus patients the diagnostic use of serum anti-a-actinin antibodies, alone or with other novel biomarkers, is still under investigation, such studies are vital in improving our monitoring of systemic lupus erythematosus patients and in developing new treatment paradigms that meet the continuing clinical challenge of lupus nephritis.
AB - Antibodies to double-stranded DNA are important in the pathogenesis of nephritis, a major clinical manifestation in lupus patients. Since earlier diagnosis of renal involvement may lead to better outcomes, identification of the nephritogenic specificity of lupus-associated autoantibodies is important in understanding the disease, while monitoring their titer clinically may serve as an improved biomarker. Based upon work in animal models and crosssectional human studies, kidney a-actinin was thought to be a plausible cross-reactive target for pathogenic lupus antibodies. Manson and colleagues longitudinally evaluated anti-nucleosome, anti-DNA, and anti-a-actinin antibodies in 16 lupus patients with new-onset nephritis. While anti-nucleosome and anti-DNA antibody levels were significantly associated and correlated with measures of kidney disease, these were not found to be significant with anti- a-actinin antibodies. While in lupus patients the diagnostic use of serum anti-a-actinin antibodies, alone or with other novel biomarkers, is still under investigation, such studies are vital in improving our monitoring of systemic lupus erythematosus patients and in developing new treatment paradigms that meet the continuing clinical challenge of lupus nephritis.
UR - http://www.scopus.com/inward/record.url?scp=77952513179&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77952513179&partnerID=8YFLogxK
U2 - 10.1186/ar2869
DO - 10.1186/ar2869
M3 - Editorial
C2 - 20017900
AN - SCOPUS:77952513179
SN - 1478-6354
VL - 11
JO - Arthritis Research and Therapy
JF - Arthritis Research and Therapy
IS - 6
M1 - 137
ER -
